257- Denadai R, et al. Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy
for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns
Colitis. 2013;7(7):517–24. - Cullen G, et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory
bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol
Ther. 2011;34(11–12):1318–27. - Ramos-Casals M, et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract
Res Clin Rheumatol. 2008;22(5):847–61. - Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antag-
onist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum.
2010;40(3):233–40. - Wolk K, et al. Excessive body weight and smoking associates with a high risk of onset of
plaque psoriasis. Acta Derm Venereol. 2009;89(5):492–7. - Pugliese D, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel
disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol
Ther. 2015;42(7):880–8. - Afzali A, et al. The association of psoriasiform rash with anti-tumor necrosis factor (anti-
TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns
Colitis. 2014;8(6):480–8. - Huang V, et al. A study investigating the association of dermatological and infusion reactions
to infliximab and infliximab trough levels. Can J Gastroenterol Hepatol. 2015;29(1):35–40. - Cleynen I, et al. Characteristics of skin lesions associated with anti-tumor necrosis fac-
tor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med.
2016;164(1):10–22. - Funk J, et al. Psoriasis induced by interferon-alpha. Br J Dermatol. 1991;125(5):463–5.
- de Gannes GC, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in
patients with rheumatologic conditions. Arch Dermatol. 2007;143(2):223–31. - Ariza ME, Williams MV. A human endogenous retrovirus K dUTPase triggers a
TH1, TH17 cytokine response: does it have a role in psoriasis? J Invest Dermatol.
2011;131(12):2419–27. - Riveira-Munoz E, et al. Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor
for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. J Invest Dermatol.
2011;131(5):1105–9. - Cantaert T, et al. Type I IFN and TNFalpha cross-regulation in immune-mediated inflamma-
tory disease: basic concepts and clinical relevance. Arthritis Res Ther. 2010;12(5):219. - Nestle FO, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha
production. J Exp Med. 2005;202(1):135–43. - Seneschal J, et al. Cytokine imbalance with increased production of interferon-alpha in
psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br
J Dermatol. 2009;161(5):1081–8. - Wollenberg A, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with
distinct role in inflammatory skin diseases. J Invest Dermatol. 2002;119(5):1096–102. - Aeberli D, et al. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA
patients with TNF-alpha inhibitors. Rheumatology. 2005;44(2):172–5. - Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis.
Clin Dermatol. 1998;16(3):333–51. - Beigel F, et al. Formation of antinuclear and double-strand DNA antibodies and frequency of
lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel
disease. Inflamm Bowel Dis. 2011;17(1):91–8. - Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev.
2010;10(1):46–50. - Ramos-Casals M, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of
233 cases. Medicine. 2007;86(4):242–51.
14 Noninfectious and Nonmalignant Complications of Anti-TNF Therapy